Gemcitabine and Cisplatin with Radiotherapy for Pancreatic Cancer
Author Information
Author(s): Hong S P, Park J Y, Jeon T J, Bang S, Park S W, Chung J B, Park M-S, Seong J, Lee W J, Song S Y
Primary Institution: Yonsei University College of Medicine
Hypothesis
The study aims to evaluate the efficacy and toxicity of a full dose of gemcitabine and a single dose of cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Conclusion
The treatment regimen of weekly full-dose gemcitabine and single-dose cisplatin combined with external radiation is effective and may prolong the survival of patients with locally advanced pancreatic cancer.
Supporting Evidence
- Forty-one patients with locally advanced pancreatic cancer were enrolled.
- The overall response rate was 24.4%, with two complete and eight partial responses.
- Six patients underwent definite pancreatic resection, and four had negative surgical margins.
- The median survival time was 16.7 months, and the 1- and 2-year survival rates were 63.3% and 27.9%, respectively.
Takeaway
Doctors tested a new treatment for pancreatic cancer using two medicines and radiation, and it helped some patients live longer.
Methodology
Patients received gemcitabine and cisplatin with concurrent radiotherapy, and their responses were evaluated based on survival rates and side effects.
Limitations
The study had limitations in accurately evaluating the resectability of primary pancreatic cancer after chemoradiotherapy.
Participant Demographics
The patient group included 22 men and 19 women with a median age of 59 years.
Statistical Information
P-Value
0.079
Confidence Interval
95% CI: 10.4–23.1 months
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website